PRA
Lenexa, Kansas, 66219, United States
NCT Number: NCT01639729
Determine whether the amount of drug absorbed is different if the tablet is placed under the tongue, placed between the cheek and gum, or swallowed.
Looking for future studies?
Notify Me18 year–45 year
All sexes
Interventional
Phase 1
Lenexa, Kansas, 66219, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Sufenta IV (50 mcg/mL) 15 mcg push over 1 minute (IV)
Single Sufentanil NanoTab 15 mcg given sublingually (SL)
Treatment C: Single Sufentanil NanoTab 15 mcg given buccally (BU)
Single Sufentanil NanoTab 15 mcg swallowed (PO)
Time frame: 24 hours
total amount of sufentanil absorbed
Time frame: 24 hours
maximum plasma concentration
Time frame: 24 hours
time to maximum plasma concentration
Time frame: 24 hours
time for maximum plasma concentration to decrease by 50%
Talphera, Inc
Industry
Effect of Delivery Route on the Pharmacokinetics of Sufentanil NanoTab® in Healthy Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07560150
Insulin Aspart, Pharmacodynamics
Chula Vista, California, United States
View Trial DetailsNCT05142592
Pharmacokinetics, Safety Issues
Portland, Oregon, United States
View Trial DetailsNCT03911050
Human Health, Pharmacokinetics
Kannapolis, North Carolina, United States
View Trial DetailsNCT05328778
Pharmacokinetics
Guangzhou, Guangdong, China
View Trial Details